Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

10/07/2020 | 04:14pm EDT

Item 7.01. Regulation FD Disclosure.

On October 7, 2020, VYNE Therapeutics Inc. (the "Company") issued a press release entitled "VYNE Therapeutics Announces Covered Status for ZILXI™ (minocycline) with Express Scripts." A copy of the press release is attached as Exhibit 99.1 to this report.

In addition, on October 5, 2020, Patrick LePore, a member of the Company's Board of Directors, entered into a stock trading plan in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Company's insider trading policy to purchase shares of the Company's common stock. Under the plan, Mr. LePore intends to purchase 200,000 shares of the Company's common stock at prevailing market prices through his broker over the next twelve months, subject to the terms of the plan. Transactions under Mr. LePore's 10b5-1 plan will be reported to the Securities and Exchange Commission in accordance with applicable securities laws, rules and regulations.

The information in this Item 7.01 and Exhibit 99.1 hereto is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits


The following exhibit is furnished herewith.



         Exhibit No.   Description
           99.1          Press Release, dated October 7, 2020.

         104           Cover Page Interactive Date File (embedded within the Inline
                       XBRL document).

© Edgar Online, source Glimpses

All news about VYNE THERAPEUTICS INC.
06/07VYNE THERAPEUTICS  : Management Change/Compensation (Form 8-K)
PU
06/07VYNE THERAPEUTICS INC.  : Change in Directors or Principal Officers (form 8-K)
AQ
05/07INSIDER TRENDS : Insider Sales Add to 90-Day Trend at VYNE Therapeutics
MT
05/07VYNE THERAPEUTICS  : HC Wainwright Adjusts VYNE Therapeutics' Price Target to $1..
MT
05/07VYNE THERAPEUTICS  : Files Shelf for Up to $200 Million in Securities
MT
05/06VYNE THERAPEUTICS REPORTS FIRST QUAR : 30 am Eastern Time
PU
05/06SECTOR UPDATE : Health Care Stocks Slip In Thursday Markets
MT
05/06SECTOR UPDATE : Health Care Stocks Declining This Afternoon
MT
05/06VYNE THERAPEUTICS  : Management's Discussion and Analysis of Financial Condition..
AQ
05/06VYNE THERAPEUTICS  : Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q1 Revenue ..
MT
More news
Financials (USD)
Sales 2021 34,0 M - -
Net income 2021 -73,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,63x
Yield 2021 -
Capitalization 184 M 184 M -
Capi. / Sales 2021 5,42x
Capi. / Sales 2022 2,36x
Nbr of Employees 106
Free-Float 83,6%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 3,59 $
Average target price 11,43 $
Spread / Average Target 218%
EPS Revisions
Managers and Directors
NameTitle
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VYNE THERAPEUTICS INC.-43.20%184
GILEAD SCIENCES, INC.14.40%83 591
WUXI APPTEC CO., LTD.36.51%69 433
BIONTECH SE181.53%55 429
REGENERON PHARMACEUTICALS9.66%54 864
VERTEX PHARMACEUTICALS-20.66%48 542